The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
1- Raises the upcoming FDA safety meeting on Injectafer (Ferinject). 2- Issues related to hypophosphatemia and cardiovascular health raised. 3- Quaestion of impact for ferumoxytol (AMAG) and other IV iron drugs.
Ferumoxytol is not likely to gain market share and widespread use by hemodialysis centers. This new iron preparation offers no benefit over Ferrlecit and Venofer. Additionally, hemodialysis patient's are not inconvenienced by 30 minute infusion versus a 5-minute infusion.
ESA's under pressure because of FDA black box warning.
Ferumoxytol has safety and efficacy data to support NDA.
Ease of use will immediately give it access to HD market and will grow pre ESRD CKD market, as is appropriate.
DDAVP reduces urine output and is useful in the treatment of bedwetting (enuresis). However the reduction in excretion of water can be associated with water intoxication (hyponatremia). FDA advises that DDAVP is no longer considered indicated for the treatment of enuresis.
High serum phosphorus is clearly associated with decreased survival in CKD patients and in the general population. As eGFR declines, the serum phosphorus rises and increases a patients risk of developing cardiovascular and bone complications. Unfortunately, it remains to be...
1. Oral erythropoiesis stimulating product may positively impact compliance in non- dialysis ckd patients 2. It would be important to see the potency of the medication. 3. Are there any drug interactions or concerning side effects
Extended Release niacin has the second highest discontinuation rate. Laropiprant is a selective antagonist of the prostaglandin D(2) receptor subtype 1, which reduces niacin-induced vasodilation. Is it better than Aspirin?!
The result of this study was not a surprise Inflammation and infection hamper the respose to EPO HIF 1 Alpha stabilizer is the answer for this group of patients